Sep 2026· Current Cancer Therapy Reviews· 0 citations
TL;DR
The JAK/STAT signaling pathway regulates processes such as proliferation, differentiation, survival, and immune responses and is strongly correlated with the initiation and progression of several malignancies in humans.
Abstract
The JAK/STAT signaling pathway regulates processes such as proliferation, differentiation,
survival, and immune responses. Dysregulation of this pathway is strongly correlated with the
initiation and progression of several malignancies in humans. This pathway consists of Janus Kinases
(JAKs) and Signal Transducers and Activators of Transcription (STATs), which together form a signaling
network with feedback regulation and extensive crosstalk with other oncogenic pathways. Cytokine
stimulation leads to JAK-mediated phosphorylation, activating STAT proteins, allowing them
to dimerize and translocate to the nucleus, where they regulate the transcription of genes involved in
angiogenesis, immune evasion, survival, and tumor growth. Hematological malignancies and solid tumours
exhibit persistent activation of JAK/STAT signaling, highlighting its role in cancer. Errors in this
signaling pathway cause sustained proliferative signaling, apoptosis resistance, and modulation of the
tumour microenvironment, all of which eventually lead to tumorigenesis. Therefore, targeting this pathway
is a promising therapeutic strategy for treating cancer. Several JAK inhibitors have been developed
and clinically approved, demonstrating their efficacy in suppressing downstream STAT activation.
A framework for mechanism-based treatment strategies in FGFR-aberrant cancers is provided by linking apoptotic regulation, immune evasion, and therapeutic resistance by linking apoptotic regulation, immune evasion, and therapeutic resistance.
Yi-Nan Hu, Xin-Miao Zhang, Wen Liu et al.· Frontiers in Immunology· 0 citations
INTRODUCTION
Cancer progression is sustained by complex interactions between oncogenic signaling pathways and immune checkpoint networks, yet their mechanistic crosstalk remains poorly integrated in existing reviews. This review synthesises the bidirectional regulatory relationships between oncogenic signaling and immu...
Praveen Kumar Chandra Sekar, R. Veerabathiran· Current Drug Targets· 0 citations
This study comprehensively investigates PI3K/AKT signaling, elucidating its involvement across diverse human systemic tumors and analyzing the interplay between this pathway and other signaling cascades implicated in tumorigenesis.
Qingmiao Shi, Jie Liu, Qing-Fei Chu et al.· Signal Transduction and Targ...· 0 citations
This review critically evaluates current evidence linking natural compounds with JAK/STAT inhibition, with particular emphasis on the emerging retinoidJAK/STAT interface and provides a framework for evaluating the therapeutic potential of retinoid-mediated JAK/STAT modulation in cancer.
Ayesha Jabeen, Tabish Javeed, Nusrat Jan et al.· Clinical and Translational O...· 0 citations
Experimental results from breast, lung, gastric, liver, hematological, and melanoma models suggest that dysregulated PDK1 signaling can increase the output of the PI3K-AKT-mTOR pathway, invasion, metabolic adaptation, and resistance to specific hormonal, chemotherapeutic, and targeted therapies.
Darshana Ballagere Honnasiddappa, M. Ramar, Tincy Biju et al.· International Journal of Bio...· 0 citations
We use cookies to run the site and, with your consent, for analytics and to show ads.
See our Cookie Policy.